Author:
Demirel Aslıhan,Ozaras Resat
Publisher
Springer International Publishing
Reference59 articles.
1. Schweitzer A, Horn J, Mikolajczyk R, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.
2. GBD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–71.
3. Yuen M, Seto W, Chow D, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12:1295–303.
4. Lim YS. Management of antiviral resistance in chronic hepatitis B. Gut Liver. 2017;11(2):189–95.
5. Terrault N, Bzowej N, Chang K, American Association for the Study of Liver Diseases, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.